Seed Therapeutics
James Finn has extensive work experience in the pharmaceutical and biotechnology industries. James started their career at Cephalon in 1995 as a Scientific Researcher and stayed with the company until 2011. In 2012, they joined DuPont as a Molecular Biologist for one year. From 2013 to 2018, they worked at Teva Pharmaceuticals as a Research Biologist, where they played a key role in identifying small molecules and leading target engagement studies. In 2018, they joined Immunome as a Senior Research Scientist and worked there until 2021. Currently, they are the Director of Operations at Seed Therapeutics.
James Finn completed their education at West Chester University of Pennsylvania, where they obtained a Bachelor's of Science degree in Biology. No specific start or end years have been provided for their education at this institution.
This person is not in any offices
Seed Therapeutics
Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.”